Insulin Lispro Sanofi (Insulin Lispro)

• Insulin Lispro is a rapid‑acting insulin used in the management of diabetes mellitus.
• Type 1 diabetes mellitus: provides rapid post‑prandial glucose reduction to achieve target glycaemic control.
• Type 2 diabetes mellitus: serves as mealtime insulin to improve overall glycaemic management.
• Intensive insulin therapy (basal‑bolus regimens): supplies the rapid‑acting component for flexible dosing.

• Insulin Lispro binds to the insulin receptor on cell membranes, activating the intrinsic tyrosine kinase activity. This triggers downstream signaling pathways that promote translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue and suppressing hepatic glucose production. Its altered amino‑acid sequence confers a faster onset and shorter duration compared with regular human insulin.

Insulin Lispro may be associated with a range of adverse reactions, ranging from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose episodes, especially if meals are missed or dose is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight due to improved glucose utilization.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Allergic rash: mild skin eruptions.

Serious or Rare Side Effects

• Severe hypoglycemia: neurological impairment requiring immediate treatment.
• Anaphylactic reaction: rare systemic allergic response with airway compromise.
• Hypokalemia: low serum potassium levels, particularly with high doses.
• Edema: fluid retention leading to swelling of extremities.
• Thrombotic events: rare clot formation at injection sites.

• When using Insulin Lispro, several precautions should be observed to ensure safe and effective therapy.
• Dose titration: adjust dose based on frequent blood glucose monitoring and clinical response.
• Hypoglycemia risk: educate patients to recognize symptoms and have rapid‑acting carbohydrate available.
• Renal impairment: reduced clearance may necessitate lower doses.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Drug interactions: monitor closely when combined with beta‑blockers, sulfonylureas, or alcohol.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Lispro can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent sulfonylureas: may cause severe hypoglycemia.
• Beta‑blockers: can mask hypoglycemia symptoms, requiring careful monitoring.
• Excessive alcohol intake: potentiates insulin’s glucose‑lowering effect, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may raise blood glucose, requiring dose adjustment.
• Glucocorticoids: increase insulin resistance, possibly needing higher insulin doses.
• ACE inhibitors: can enhance insulin sensitivity, potentially leading to hypoglycemia.